FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 79 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Army Veteran Gets Life-Saving Heart Transplant: ‘It’s A True Miracle’ November 29, 2021 Most Tattoo Artists Want to Show Off Their Work. These Nipple... August 2, 2019 The team of over 60 scientists investigating the age-old mystery of... September 24, 2020 Dad Is Making Baby Giggle, But When He Makes A Sheep... May 21, 2019 Load more HOT NEWS Multiple Myeloma Awareness Month: Inequity and Disparities in Multiple Myeloma Diagnosis,... Coping With Cancer Recurrence: My Perspective As Both a Patient and... Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... 4 Tips from Oncology Dietitians for Healthier Eating During Cancer
